8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Apr 8, 2026·SEC
TuHURA Biosciences, Inc.(HURA)Earnings, Financials & Key Ratios
HURA•NASDAQ
Price updated Jun 19, 2026
AboutTuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.Show more
- Revenue$0
- EBITDA-$32M-80.9%
- Net Income-$30M-38.6%
- EPS (Diluted)-0.63+48.1%
- ROE-169.23%+49.1%
HURA Key Insights
TuHURA Biosciences, Inc. (HURA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 89 (top 11%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HURA Price & Volume
TuHURA Biosciences, Inc. (HURA) stock price & volume — 10-year historical chart
Loading chart...
HURA Growth Metrics
TuHURA Biosciences, Inc. (HURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM96.43%
Return on Capital
10 Years-291.21%
5 Years-248.63%
3 Years-178.2%
Last Year-176.3%
HURA Recent Earnings
TuHURA Biosciences, Inc. (HURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.13-8.3%
$0.12
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.13-1.4%
$0.12
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.14+6.7%
$0.15
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.21-50.0%
$0.14
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.13vs $0.12-8.3% | — |
| Q2 2026 | Mar 31, 2026 | $0.13vs $0.12-1.4% | — |
| Q4 2025 | Nov 14, 2025 | $0.14vs $0.15+6.7% | — |
| Q3 2025 | Aug 14, 2025 | $0.21vs $0.14-50.0% | — |
Based on last 12 quarters of dataView full earnings history →
HURA Peer Comparison
TuHURA Biosciences, Inc. (HURA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 |
Compare HURA vs Peers
TuHURA Biosciences, Inc. (HURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HURA Income Statement
TuHURA Biosciences, Inc. (HURA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 24.53K | 16.35K | 10K | 32K | 60K | 60K | 55K | 0 | 0 | 23.47K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -24.53K▲ 0% | -16.35K▲ 33.3% | -10K▲ 38.8% | -32K▼ 220.0% | -60K▼ 87.5% | -60K▲ 0.0% | -55K▲ 8.3% | 0▲ 100.0% | 0▲ 0% | -23.47K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -47.02% | 33.35% | 38.83% | -220% | -87.5% | 0% | 8.33% | 100% | - | - |
Operating Expenses | 11.15M | 8.38M | 8.13M | 21.54M | 22.62M | 14.74M | 8.4M | 17.65M | 31.8M | 32.29M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 4.02M | 4.72M | 4.5M | 9.72M | 7.45M | 5.42M | 5.73M | 4.31M | 7.58M | 7.45M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 7.13M | 3.66M | 3.63M | 11.81M | 15.17M | 9.31M | 2.66M | 13.34M | 20.53M | 21.18M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.68M | 1000K |
Operating Income | -11.17M▲ 0% | -8.4M▲ 24.8% | -8.14M▲ 3.0% | -21.57M▼ 164.9% | -22.68M▼ 5.1% | -14.8M▲ 34.8% | -8.45M▲ 42.9% | -17.65M▼ 108.8% | -31.8M▼ 80.2% | -32.31M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -34.3% | 24.84% | 3.03% | -164.88% | -5.15% | 34.77% | 42.88% | -108.84% | -80.15% | - |
EBITDA | -11.15M | -8.38M | -8.13M | -21.54M | -22.62M | -14.74M | -8.4M | -17.53M | -31.72M | -32.23M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -34.27% | 24.82% | 2.96% | -164.81% | -5.02% | 34.86% | 43.02% | -108.82% | -80.94% | -53.81% |
D&A (Non-Cash Add-back) | 24.53K | 16.35K | 10K | 32K | 60K | 60K | 55K | 116.71K | 71.27K | 80.68K |
EBIT | -11.14M | -8.05M | -9.13M | -38.18M | -22.68M | -14.8M | -8.32M | -17.54M | -29.43M | -30.29M |
Net Interest Income | 33.24K | 60.7K | 75K | -120K | -629.29K | 57.35K | 70.98K | -3.78M | -489.05K | -595.85K |
Interest Income | 33.24K | 60.7K | 75K | 0 | 0 | 57.35K | 89.67K | 361.63K | 136.23K | 57.41K |
Interest Expense | 0 | 0 | 0 | 120K | 629.29K | 0 | 18.69K | 4.14M | 625.28K | 653.26K |
Other Income/Expense | 36.35K | 350.27K | -982K | -16.73M | 21K | 147K | 131K | -4.03M | 1.74M | 1.38M |
Pretax Income | -11.14M▲ 0% | -8.05M▲ 27.7% | -9.13M▼ 13.4% | -38.3M▼ 319.7% | -22.66M▲ 40.8% | -14.65M▲ 35.4% | -8.32M▲ 43.2% | -21.68M▼ 160.6% | -30.06M▼ 38.6% | -30.92M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -11.14M▲ 0% | -8.05M▲ 27.7% | -9.13M▼ 13.4% | -38.3M▼ 319.7% | -22.66M▲ 40.8% | -14.65M▲ 35.4% | -8.32M▲ 43.2% | -21.68M▼ 160.6% | -30.06M▼ 38.6% | -30.93M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -37.82% | 27.74% | -13.39% | -319.66% | 40.83% | 35.36% | 43.2% | -160.6% | -38.64% | -34.01% |
Net Income (Continuing) | -11.14M | -8.05M | -9.13M | -38.3M | -22.66M | -14.65M | -8.32M | -21.68M | -30.06M | -30.92M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -9491.48▲ 0% | -5525.00▲ 41.8% | -1532.00▲ 72.3% | -2805.85▼ 83.1% | -903.04▲ 67.8% | -324.48▲ 64.1% | -11.29▲ 96.5% | -1.21▲ 89.3% | -0.63▲ 48.1% | -0.52▲ 0% |
EPS Growth % | 26.71% | 41.79% | 72.27% | -83.15% | 67.82% | 64.07% | 96.52% | 89.25% | 48.09% | 96.43% |
EPS (Basic) | -9491.48 | -5525.00 | -1532.00 | -2805.85 | -903.04 | -324.48 | -11.29 | -1.21 | -0.63 | - |
Diluted Shares Outstanding | 1.19K | 1.47K | 5.97K | 14.79K | 27.83K | 46.28K | 752.91K | 18.66M | 47.93M | 60.01M |
Basic Shares Outstanding | 1.19K | 1.47K | 5.97K | 14.79K | 27.83K | 46.28K | 752.91K | 18.66M | 47.93M | 60.01M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
HURA Balance Sheet
TuHURA Biosciences, Inc. (HURA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.05M | 4.03M | 2.76M | 11.79M | 5.68M | 14.74M | 4.16M | 19.61M | 4.62M | 6.98M |
Cash & Short-Term Investments | 5.97M | 3.72M | 2.39M | 10.54M | 5.55M | 14.25M | 3.67M | 12.66M | 3.62M | 6.3M |
Cash Only | 5.97M | 3.72M | 2.39M | 10.54M | 5.55M | 14.25M | 3.67M | 12.66M | 3.62M | 6.3M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 39.52K | 26.19K | 0 | 0 | 0 | 101.42K | 334.44K | 222.7K | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 214.7K | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.03M | 280.25K | 365K | 1.26M | 135.13K | 390.35K | 159.33K | 316.35K | 1M | 367.51K |
Total Non-Current Assets | 28.41K | 12.06K | 181K | 1.75M | 721.04K | 452.32K | 202.99K | 356.3K | 22.73M | 22.72M |
Property, Plant & Equipment | 0 | 0 | 2K | 150K | 617.14K | 418.55K | 202.99K | 322.53K | 685.17K | 675.64K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.74M | 10.74M |
Intangible Assets | 28.41K | 12.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.28M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 179K | 1.6M | 103.9K | 33.77K | 0 | 33.77K | 11.31M | 33.77K |
Total Assets | 7.07M▲ 0% | 4.04M▼ 42.9% | 2.94M▼ 27.2% | 13.54M▲ 361.0% | 6.4M▼ 52.7% | 15.2M▲ 137.4% | 4.36M▼ 71.3% | 19.97M▲ 357.8% | 27.35M▲ 37.0% | 29.7M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -10.57% | -42.94% | -27.23% | 360.96% | -52.73% | 137.36% | -71.3% | 357.76% | 36.99% | 660.62% |
Total Current Liabilities | 1.64M | 2.07M | 2.67M | 2.78M | 7.15M | 2.87M | 3.6M | 5.33M | 5.92M | 6.07M |
Accounts Payable | 1.48M | 1.74M | 2.01M | 2.22M | 413.79K | 1.92M | 1.87M | 3.15M | 0 | 3.95M |
Days Payables Outstanding | 22K | 38.95K | 73.4K | 25.31K | 2.52K | 11.65K | 12.39K | - | - | 31.42K |
Short-Term Debt | 0 | 0 | 0 | 0 | 644.07K | 0 | 0 | 0 | 199.04K | 206.85K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 160.43K | 325.21K | 664K | 561K | 456K | 675K | 137K | 1.16M | 5.72M | 197.59K |
Current Ratio | 4.30x | 1.94x | 1.03x | 4.24x | 0.79x | 5.13x | 1.16x | 3.68x | 0.78x | 1.15x |
Quick Ratio | 4.30x | 1.94x | 1.03x | 4.24x | 0.79x | 5.13x | 1.16x | 3.64x | 0.78x | 1.15x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 1.12K | 0 | 0 | 182K | 0 | 20.74K | 2.32M | 42.7K | 501.55K | 447.99K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.32M | 0 | 303.63K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 20.74K | 0 | 42.7K | 0 | 250.07K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 197.92K | 395.84K |
Other Non-Current Liabilities | 1.12K | 0 | 0 | 182K | 0 | 0 | 0 | 0 | 0 | -1 |
Total Liabilities | 1.64M | 2.07M | 2.67M | 2.96M | 7.15M | 2.89M | 5.92M | 5.37M | 6.42M | 6.51M |
Total Debt | 0 | 0 | 0 | 0 | 644.07K | 138.22K | 2.34M | 202.54K | 502.67K | 456.93K |
Net Debt | -5.97M | -3.72M | -2.39M | -10.54M | -4.9M | -14.11M | -1.32M | -12.45M | -3.12M | -5.84M |
Debt / Equity | - | - | - | - | - | 0.01x | - | 0.01x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.18x |
Interest Coverage | - | - | - | -318.15x | -36.04x | - | -445.21x | -4.24x | -47.06x | -46.37x |
Total Equity | 5.44M▲ 0% | 1.97M▼ 63.8% | 263K▼ 86.6% | 10.58M▲ 3923.2% | -747.82K▼ 107.1% | 12.3M▲ 1745.3% | -1.56M▼ 112.7% | 14.59M▲ 1036.3% | 20.93M▲ 43.4% | 23.19M▲ 0% |
Equity Growth % | -17.38% | -63.8% | -86.63% | 3923.19% | -107.07% | 1745.31% | -112.67% | 1036.26% | 43.43% | 1068.56% |
Book Value per Share | 4559.75 | 1337.55 | 44.07 | 715.37 | -26.87 | 265.83 | -2.07 | 0.78 | 0.44 | 0.39 |
Total Shareholders' Equity | 5.44M | 1.97M | 263K | 10.58M | -747.82K | 12.3M | -1.56M | 14.59M | 20.93M | 23.19M |
Common Stock | 22.97K | 3.84K | 11K | 33K | 4.53K | 4.53K | 6.8K | 42.32K | 59.34K | 63.58K |
Retained Earnings | -52.44M | -60.58M | -69.72M | -111.22M | -49.48M | -59.16M | -88.47M | -111.12M | -141.18M | -148.72M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 8.25M | 6.61M | 21K | 21K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HURA Cash Flow Statement
TuHURA Biosciences, Inc. (HURA) cash flow — operating, investing & free cash flow history
| Metric | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.85M | -6.33M | -7.93M | -18.86M | -6.56M | -7.51M | -7.18M | -14.73M | -27.63M | -27.3M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -22.84% | 35.77% | -25.3% | -137.89% | 65.2% | -14.4% | 4.43% | -105.24% | -87.59% | -593.76% |
Net Income | -11.14M | -8.05M | -9.13M | -38.3M | -7.02M | -9.37M | -29.32M | -21.68M | -30.05M | -30.93M |
Depreciation & Amortization | 24.53K | 16.35K | 10K | 32K | 380.69K | 373.09K | 177.38K | 116.71K | 71.27K | 80.68K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 654.53K | 218.28K | 478.89K | 1.96M | 6.42M | 5M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 685.42K | 569.65K | 701K | 22.06M | -527.06K | -294.07K | 21M | 1.59M | -924.5K | 1.87M |
Working Capital Changes | 577.51K | 1.13M | 487K | -2.65M | -55K | 1.56M | 486.92K | 3.29M | -3.15M | -3.33M |
Change in Receivables | 37.08K | 13.33K | 16.79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 295.77K | 202K | 207K | -67K | 0 | 0 | 0 | 0 | 0 | 452.01K |
Cash from Investing | -12.65K | 0 | 0 | 964K | -3.28K | -36.28K | -1.3M | -6.05M | -1.34M | -233.16K |
Capital Expenditures | -12.65K | 0 | 0 | -8K | -3.28K | -36.28K | -79.22K | -57.91K | -76.08K | -82.26K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 972K | 0 | 0 | -1.22M | -5.99M | -1.26M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -150.9K |
Cash from Financing | 9.25M | 4.07M | 6.6M | 26.04M | 7.04M | 16.25M | 2.66M | 29.77M | 19.93M | 27.62M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 294.07K | -350K | 2.69M | 28.57M | 616.98K | 408.78K |
Equity Issued (Net) | 9.26M | 4.08M | 6.63M | 26.08M | 6.75M | 16.6M | -24.75K | 5M | 21.92M | 22.86M |
Dividends Paid | -8.36K | -8.36K | -8K | -8K | -8K | 0 | 0 | 0 | -8.36K | -8.36K |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -24.75K | 0 | 0 | 0 |
Other Financing | 0 | 0 | -25K | -30K | 8K | 0 | 0 | -3.8M | -2.61M | 4.36M |
Net Change in Cash | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 477.91K▲ 0% | 8.71M▲ 1721.8% | -10.59M▼ 221.6% | 8.99M▲ 184.9% | -9.04M▼ 200.5% | 78.3K▲ 0% |
Free Cash Flow | 0▲ 0% | -6.33M▲ 0% | -7.93M▼ 25.3% | -18.87M▼ 138.0% | -6.57M▲ 65.2% | -7.54M▼ 14.9% | -12.03M▼ 59.5% | -14.79M▼ 22.9% | -27.71M▼ 87.4% | -27.39M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 100% | - | -25.3% | -137.99% | 65.2% | -14.89% | -59.45% | -22.91% | -87.37% | -108.65% |
FCF per Share | - | -4301.44 | -1328.42 | -1275.64 | -235.96 | -163.00 | -15.98 | -0.79 | -0.58 | -0.46 |
FCF Conversion (FCF/Net Income) | 0.88x | 0.79x | 0.87x | 0.49x | 0.29x | 0.51x | 0.86x | 0.68x | 0.92x | 0.89x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HURA Key Ratios
TuHURA Biosciences, Inc. (HURA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -185.43% | -217.44% | -818.28% | -706.34% | -460.91% | -253.53% | -154.86% | -332.67% | -169.23% | -153.99% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | -239.01% | -158.07% |
Debt / Equity | - | - | - | - | - | 0.01x | - | 0.01x | 0.02x | 0.02x |
Interest Coverage | - | - | - | -318.15x | -36.04x | - | -445.21x | -4.24x | -47.06x | -46.37x |
FCF Conversion | 0.88x | 0.79x | 0.87x | 0.49x | 0.29x | 0.51x | 0.86x | 0.68x | 0.92x | 0.89x |
Related:HURA Dividend History·HURA Revenue History·HURA Price History·HURA P/E History·HURA Financial Ratios·HURA Institutional Holders
HURA SEC Filings & Documents
TuHURA Biosciences, Inc. (HURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
HURA Frequently Asked Questions
TuHURA Biosciences, Inc. (HURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TuHURA Biosciences, Inc. (HURA) grew revenue by 0.0% over the past year. Growth has been modest.
TuHURA Biosciences, Inc. (HURA) reported a net loss of $30.9M for fiscal year 2025.
Dividend & Returns
TuHURA Biosciences, Inc. (HURA) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
TuHURA Biosciences, Inc. (HURA) has a return on equity (ROE) of -169.2%. Negative ROE indicates the company is unprofitable.
TuHURA Biosciences, Inc. (HURA) had negative free cash flow of $27.4M in fiscal year 2025, likely due to heavy capital investments.